Cargando…

Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hypertension

We previously reported that osteoprotegerin (OPG) is regulated by pathways associated with pulmonary arterial hypertension (PAH), and is present at elevated levels within pulmonary vascular lesions and sera from patients with idiopathic PAH (IPAH). Since OPG is a naturally secreted protein, we inves...

Descripción completa

Detalles Bibliográficos
Autores principales:	Condliffe, Robin, Pickworth, Josephine A., Hopkinson, Kay, Walker, Sara J., Hameed, Abdul G., Suntharaligam, Jay, Soon, Elaine, Treacy, Carmen, Pepke-Zaba, Joanna, Francis, Sheila E., Crossman, David C., Newman, Christopher M. H., Elliot, Charles A., Morton, Allison C., Morrell, Nicholas W., Kiely, David G., Lawrie, Allan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342744/ https://www.ncbi.nlm.nih.gov/pubmed/22558516 http://dx.doi.org/10.4103/2045-8932.94819

Ejemplares similares

A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension
por: Arnold, Nadine D., et al.
Publicado: (2019)

Inhibition of tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension
por: Hameed, Abdul G., et al.
Publicado: (2012)

Differential IL-1 signaling induced by BMPR2 deficiency drives pulmonary vascular remodeling
por: Pickworth, Josephine, et al.
Publicado: (2017)

Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension
por: Toshner, Mark R., et al.
Publicado: (2010)

Osteoprotegerin in Cardiometabolic Disorders
por: Pérez de Ciriza, C., et al.
Publicado: (2015)

Log-transformation improves the prognostic value of serial NT-proBNP levels in apparently stable pulmonary arterial hypertension
por: Soon, Elaine, et al.
Publicado: (2011)

A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach
por: Errington, Niamh, et al.
Publicado: (2021)

(18)FDG PET imaging can quantify increased cellular metabolism in pulmonary arterial hypertension: A proof-of-principle study
por: Hagan, Guy, et al.
Publicado: (2011)

Different Cytokine Patterns in BMPR2-Mutation-Positive Patients and Patients With Pulmonary Arterial Hypertension Without Mutations and Their Influence on Survival
por: Schwiening, Max, et al.
Publicado: (2022)

Maximal Cardiac Output Determines 6 Minutes Walking Distance in Pulmonary Hypertension
por: Deboeck, Gaël, et al.
Publicado: (2014)

Author's reply
por: Pepke-Zaba, Joanna
Publicado: (2012)

Elevated Plasma CXCL12α Is Associated with a Poorer Prognosis in Pulmonary Arterial Hypertension
por: McCullagh, Brian N., et al.
Publicado: (2015)

Assessment of Right Ventricular Function—a State of the Art
por: Hameed, Abdul, et al.
Publicado: (2023)

Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood
por: Kariotis, Sokratis, et al.
Publicado: (2021)

Author Correction: Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood
por: Kariotis, Sokratis, et al.
Publicado: (2022)

Supplementation of iron in pulmonary hypertension: Rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension
por: Howard, Luke S.G.E., et al.
Publicado: (2013)

Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension
por: Boehm, Mario, et al.
Publicado: (2018)

Correction to: Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension
por: Boehm, Mario, et al.
Publicado: (2022)

Interventricular septal angle can be used to predict which patients have combined postcapillary or precapillary pulmonary hypertension in left heart disease
por: Hussain, Nehal, et al.
Publicado: (2015)

Chronic thromboembolic pulmonary hypertension: time for research in pathophysiology to catch up with developments in treatment
por: Toshner*, Mark, et al.
Publicado: (2014)

Therapeutic implications of osteoprotegerin
por: Fili, Sofia, et al.
Publicado: (2009)

The role of osteoprotegerin in arthritis
por: Schett, Georg, et al.
Publicado: (2003)

Soluble P-Selectin and von Willebrand Factor Rise in Healthy Volunteers Following Non-exertional Ascent to High Altitude
por: Turton, Helena A., et al.
Publicado: (2022)

Pulmonary Artery Denervation Reduces Pulmonary Artery Pressure and Induces Histological Changes in an Acute Porcine Model of Pulmonary Hypertension
por: Rothman, Alexander M.K., et al.
Publicado: (2015)

The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension
por: Quadery, Syed Rehan, et al.
Publicado: (2018)

Idiopathic pulmonary arterial hypertension and co-existing lung disease: is this a new phenotype?
por: Peacock, Andrew J., et al.
Publicado: (2020)

Expression of osteoprotegerin and osteoprotegerin ligand in giant cell tumor of bone and its clinical significance
por: YU, XIUCHUN, et al.
Publicado: (2013)

Cardiac MRI characteristics in patients with borderline pulmonary hypertension: results from the ASPIRE registry
por: Walker, Henry, et al.
Publicado: (2015)

Pathophysiology and Diagnosis of Pulmonary Hypertension Due to Left Heart Disease
por: Charalampopoulos, Athanasios, et al.
Publicado: (2018)

Biology of RANK, RANKL, and osteoprotegerin
por: Boyce, Brendan F, et al.
Publicado: (2007)

BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing?
por: Lewis, Robert A., et al.
Publicado: (2020)

Lifting the fog in intermediate-risk (submassive) PE: full dose, low dose, or no thrombolysis?
por: Bhamani, Amyn, et al.
Publicado: (2019)

Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension
por: Rhodes, Christopher J., et al.
Publicado: (2017)

Osteoprotegerin (OPG) gene therapy in animal models of osteoarticular disease
por: Bolon, B, et al.
Publicado: (2001)

Combining creative writing and narrative analysis to deliver new insights into the impact of pulmonary hypertension
por: Goddard, Julia C, et al.
Publicado: (2017)

Screening strategies for pulmonary arterial hypertension
por: Kiely, David G, et al.
Publicado: (2019)

Repeatability and sensitivity to change of non-invasive end points in PAH: the RESPIRE study
por: Swift, Andrew J, et al.
Publicado: (2021)

Osteoprotegerin protects from generalized bone loss in TNF-transgenic mice
por: Hayer, S, et al.
Publicado: (2003)

Predictors of outcomes in mild pulmonary hypertension according to 2022 ESC/ERS Guidelines: the EVIDENCE-PAH UK study
por: Karia, Nina, et al.
Publicado: (2023)

Critical care outcomes in patients with pre-existing pulmonary hypertension: insights from the ASPIRE registry
por: Bauchmuller, Kris, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jtmcho12kopg6dvbovmjsbgp2l